Clinical Medicine Research
Volume 2, Issue 4, July 2013, Pages: 89-93
Received: Aug. 6, 2013;
Published: Aug. 30, 2013
Views 2826 Downloads 168
Alena ADAMIKOVA, Diabetes Center, Bata Regional Hospital, Zlín, Czech Republic
Jiri BAKALA, Department of Nuclear Medicine, Bata Regional Hospital, Zlín, Czech Republic
Jana PATEROVA, Department of Nuclear Medicine, Bata Regional Hospital, Zlín, Czech Republic
Martin SLABAK, Cardiovascular Center, Bata Regional Hospital, Zlín, Czech Republic
Stepan SVACINA, First Faculty of Medicine, Charles University, Prague, Czech Republic
Diabetic cardiomyopathy is defined as a finding of systolic and diastolic left ventricular dysfunction, myocardial dilation and left ventricular hypertrophy without the presence of macroangiopathy and hypertension. Causes include metabolic changes, myocardial fibrosis, microangiopathy as well as cardiovascular autonomic neuropathy leading to sympathetic denervation and alteration of myocardial perfusion. It comprises abnormalities in the control of heart rate as well as central and peripheral vascular dynamics. The diagnosis of diabetic cardiomyopathy affects significantly the prognosis in patients with diabetes. Echocardiography and nuclear medicine methods are used for diagnosis.
Diabetic Cardiomyopathy - Heart Disease in Diabetes, Clinical Medicine Research.
Vol. 2, No. 4,
2013, pp. 89-93.
D. Ziegler, C. P. Zentai and S. Perz S. Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population The MONICA/KORA Augsburg Cohort Study. Diabetes Care 2008; 31, pp. 556-561.
A. I. Vinik, RE. Maser and BD. Mitchell. Diabetic autonomic neuropathy. Diabetes Care 2003; 26 (5), pp. 1553-1579.
P. Spirito, P. Bellone, K. M. Harris, P. Bernabo, P. Bruzzi and B. J. Maron. Magnitude of left ventricular hypertrophy and risk sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342, pp. 1778-1785.
C. Voulgari, D. Papadogiannis and N. Tentolouris. Diabetic cardiomyopathy: from the pathophysiology of cardiac myocytes to current diagnosis and management strategies. Vascular Health and Risk Management 2010; 6, pp. 883-903.
S. Lacigova, J. Meinlova and J. Gruberova. The heart of patient with type 1 diabetes. Vnitř Lék 2010; 56(5), pp. 418-426.
M. Petretta,W. Acampa and S. Daniele. Transient ischemic dilation in SPECT myocardial perfusion imaging for prediction of severe coronary artery disease in diabetic patients. J Nucl Cardiol 2012; doi: 10. 1007/s12350-012-9642-6.
A. Adamikova, J. Bakala, J. Bernatek, J. Rybka and S. Svacina. Transient ischemic dilation ratio (TID) correlates with HbA1c in patients with diabetes type 2 with proven myocardial ischemia according to exercise myocardial SPECT. Ann Nucl Med 2006; 20(9), pp. 615-621.
C. Tei. New non-invasive index for combined systolic and diastolic ventricular function. J Cardiol 1995; 26, pp. 135-136.
C. Tei, L. H. Ling, D. O. Hodge, K. R. Bailey, J. K. Oh and J. K.Tajik. New index of combined systolic and diastolic myocardial performance: a simple and reproducibile measure of cardiac function: a study in normal and dilated cardiomyopathy. J Cardiol 1995; 26, pp. 357-366.
C. Voulgari, N. Tentolouris and D. Papadagiannis. Increased left ventricular arrhytmogenicity in metabolic syndrome and relationship with myocardial performance, risk factors for athrerosclerosis, and low-grade inflammation. Metabolism 2010; 59, pp. 159-165.
B. Nørager, M. Husic, J. E. Møller and K. Egstrup. The myocardial performance index during low-dose dobutamine echocardiography in control subjects and patients with a recent myocardial infarction: a new index of left ventricular functional reserve? Journal of the American Society of echocardiography 2004; 17(7), pp. 732-738.
L. H. Ling, C. Tei, R. B. McCully, K. R. Bailey, J. B. Seward and P. A. Pellikka. Analysis of systolic and diastolic time intervals during dobutamie-atropine stress echocardiography: Diagnostic potencial of the doppler myocardial performance index. Journal of the American Society of Echocardiography 2001; 14(10), pp. 978-986.
S. Murashima, K. Takeda, K. Matsumura, K. Yamakado, H. Sakuma and T. Nakagawa. Increased lung uptake of Iodine-123-MIBG in diabetics with sympathetic nervous dysfunction. J Nucl Med 1998; 39(2), pp. 334-338.
A. Scott and P. L. Kench. Cardiac autonomic neuropathy in diabetic patient: does 123I-MIBG imaging have role to play in early diagnosis? J Nucl Med Technol 2004; 32, pp. 66-71.
J. Bakala, J. Bernatek, P. Kurfürst and A. Adamikova. Comparison cardiac adrenergic innervation between patients with and without diabetes mellitus using 123IMIBG planar scintigraphy and SPECT method. [abstract] Cas Lék Ces 2011; 150(2), pp. 116-117.
S. Nagamachi, S. Jinnouchi, T. Kurose, R. Nishii, K. Kawai and S. Futami. Serial chase in 123I-MIBG myocardial scintigraphy in non-insulin-depender diabetes melllitus. Ann Nucl Med 2002; 16(1), pp. 33-38.
D. Agostini, H. J. Verberne, M. Hamon, AF. Jacobson and A. Manrique. Cardiac 123I-MIBG scintigraphy in heart failure. J Nucl Med Mol Imaging 2008; 52(4), pp. 369-77.
D. Agostini, I. Carrrio and H. J. Verberne. How to use myocardial 123I-MIBG scintigraphy in chronic heart failure. Eur J Nucl Med Mol Imaging 2009; 36, pp. 555-559.
A. F. Jacobson, J. Lombard, G. Banerjee and P. G. Camici. 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: designe of two prospective multicenter international trials. J Nucl Card 2009; 16(1), pp. 113-21.
S. Hughes. ACC: ADMIRE-HF: new imaging test helps better define risk in heart failure. 2009; http://www.medscape.com/viewarticle/590516.